Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 63

1.

Gene Deletions in BCG Stimulate Increased CD8+ T Cell Responses.

Panas MW, Sixsmith JD, White K, Korioth-Schmitz B, Shields ST, Moy BT, Lee S, Schmitz JE, Jacobs WR Jr, Porcelli SA, Haynes BF, Letvin NL, Gillard GO.

Infect Immun. 2014 Oct 6. pii: IAI.02100-14. [Epub ahead of print]

PMID:
25287928
[PubMed - as supplied by publisher]
2.

Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

Partridge AH, Rumble RB, Carey LA, Come SE, Davidson NE, Di Leo A, Gralow J, Hortobagyi GN, Moy B, Yee D, Brundage SB, Danso MA, Wilcox M, Smith IE.

J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.

PMID:
25185096
[PubMed - in process]
3.

Measuring decision quality: psychometric evaluation of a new instrument for breast cancer chemotherapy.

Lee CN, Wetschler MH, Chang Y, Belkora JK, Moy B, Partridge A, Sepucha KR.

BMC Med Inform Decis Mak. 2014 Aug 20;14:73. doi: 10.1186/1472-6947-14-73.

PMID:
25142035
[PubMed - in process]
Free PMC Article
4.

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, Gonzalez-Angulo AM, Moy B, Rugo HS, Theriault RL, Weeks JC, Winer EP, Lin NU.

J Clin Oncol. 2014 Jul 10;32(20):2142-50. doi: 10.1200/JCO.2013.53.1608. Epub 2014 Jun 2.

PMID:
24888816
[PubMed - indexed for MEDLINE]
5.

Value of cancer care: ethical considerations for the practicing oncologist.

Jagsi R, Sulmasy DP, Moy B.

Am Soc Clin Oncol Educ Book. 2014:e146-9. doi: 10.14694/EdBook_AM.2014.34.e146.

PMID:
24857095
[PubMed - in process]
Free Article
6.

Geriatric oncology for the 21st century: a call for action.

Moy B, Flaig TW, Muss HB, Clark B, Tse W, Windham TC.

J Oncol Pract. 2014 Jul;10(4):241-3. doi: 10.1200/JOP.2013.001333. Epub 2014 Apr 29. No abstract available.

PMID:
24781365
[PubMed - in process]
7.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):348-9. doi: 10.1634/theoncologist.2014-0021. Epub 2014 Mar 27.

PMID:
24674874
[PubMed - in process]
Free PMC Article
8.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, Turnbull K, Bardy-Bouxin N, Duvillié L, Láng I.

Oncologist. 2014 Apr;19(4):346-7. doi: 10.1634/theoncologist.2014-0022. Epub 2014 Mar 27.

PMID:
24674873
[PubMed - in process]
Free PMC Article
9.

Massachusetts general hospital: improving patient access to the breast oncology clinic.

Lennes IT, Bloom M, Bohlen N, Moy B.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S25-7.

PMID:
24614048
[PubMed - in process]
10.

Ethical considerations for the clinical oncologist in an era of oncology drug shortages.

Jagsi R, Spence R, Rathmell WK, Bradbury A, Peppercorn J, Grubbs S, Moy B.

Oncologist. 2014 Feb;19(2):186-92. doi: 10.1634/theoncologist.2013-0301. Epub 2014 Jan 21.

PMID:
24449096
[PubMed - in process]
11.

Hemodynamic signature of breast cancer under fractional mammographic compression using a dynamic diffuse optical tomography system.

Carp SA, Sajjadi AY, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Isakoff SJ.

Biomed Opt Express. 2013 Nov 22;4(12):2911-24. doi: 10.1364/BOE.4.002911. eCollection 2013.

PMID:
24409390
[PubMed]
Free PMC Article
12.

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases.

Lin NU, Freedman RA, Ramakrishna N, Younger J, Storniolo AM, Bellon JR, Come SE, Gelman RS, Harris GJ, Henderson MA, Macdonald SM, Mahadevan A, Eisenberg E, Ligibel JA, Mayer EL, Moy B, Eichler AF, Winer EP.

Breast Cancer Res Treat. 2013 Nov;142(2):405-14. doi: 10.1007/s10549-013-2754-0. Epub 2013 Nov 7.

PMID:
24197661
[PubMed - indexed for MEDLINE]
13.

Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer.

Morris PG, Iyengar NM, Patil S, Chen C, Abbruzzi A, Lehman R, Steingart R, Oeffinger KC, Lin N, Moy B, Come SE, Winer EP, Norton L, Hudis CA, Dang CT.

Cancer. 2013 Nov 15;119(22):3943-51. doi: 10.1002/cncr.28284. Epub 2013 Aug 26.

PMID:
24037735
[PubMed - indexed for MEDLINE]
14.

Correlation between financial relationships with commercial interests and research prominence at an oncology meeting.

Moy B, Bradbury AR, Helft PR, Egleston BL, Sheikh-Salah M, Peppercorn J.

J Clin Oncol. 2013 Jul 20;31(21):2678-84. doi: 10.1200/JCO.2012.46.6375. Epub 2013 Jun 17.

PMID:
23775973
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Cancer health disparities and the cost of cancer care: payment model issues.

Kumar P, Moy B.

J Natl Compr Canc Netw. 2013 Jun 1;11(6):633-6. No abstract available.

PMID:
23744862
[PubMed - indexed for MEDLINE]
16.

The cost of cancer care--balancing our duties to patients versus society: are they mutually exclusive?

Kumar P, Moy B.

Oncologist. 2013;18(4):347-9. doi: 10.1634/theoncologist.2013-0078. Epub 2013 Apr 8. No abstract available.

PMID:
23568002
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

Goss PE, Smith IE, O'Shaughnessy J, Ejlertsen B, Kaufmann M, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Chavarri-Guerra Y, Aktan G, Rappold E, Williams LS, Finkelstein DM; TEACH investigators.

Lancet Oncol. 2013 Jan;14(1):88-96. doi: 10.1016/S1470-2045(12)70508-9. Epub 2012 Dec 10. Erratum in: Lancet Oncol. 2013 Feb;14(2):e47.

PMID:
23234763
[PubMed - indexed for MEDLINE]
18.

Ethical challenges: caring for the underinsured, geographically disadvantaged patient.

Riley EC, Moy B.

J Oncol Pract. 2012 Jul;8(4):215-8. doi: 10.1200/JOP.2012.000603. No abstract available.

PMID:
23180985
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort study.

Vaz-Luis I, Ottesen RA, Hughes ME, Marcom PK, Moy B, Rugo HS, Theriault RL, Wilson J, Niland JC, Weeks JC, Lin NU.

Breast Cancer Res. 2012 Oct 1;14(5):R129. doi: 10.1186/bcr3324.

PMID:
23025714
[PubMed - in process]
Free PMC Article
20.

Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy.

Boutrus RR, Abi Raad RF, Kuter I, Ancukiewicz M, Roberts L, Solomon N, Ngo T, Borick H, Ryan P, Moy B, Gadd M, Chien J, Younger J, Smith B, Taghian AG, Harris L.

Int J Biol Markers. 2013 Apr 23;28(1):17-23. doi: 10.5301/JBM.2012.9580.

PMID:
23015398
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk